Novo Nordisk A/S (NONOF)
128.75
+1.03
(+0.81%)
USD |
OTCM |
May 10, 16:00
Novo Nordisk Revenue (Quarterly): 7.936B for June 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2023 | 7.936B |
March 31, 2023 | 7.696B |
December 31, 2022 | 6.611B |
September 30, 2022 | 6.169B |
June 30, 2022 | 5.908B |
March 31, 2022 | 6.340B |
December 31, 2021 | 5.896B |
September 30, 2021 | 5.648B |
June 30, 2021 | 5.355B |
March 31, 2021 | 5.480B |
December 31, 2020 | 5.148B |
September 30, 2020 | 4.858B |
June 30, 2020 | 4.431B |
March 31, 2020 | 5.001B |
December 31, 2019 | 4.806B |
September 30, 2019 | 4.510B |
June 30, 2019 | 4.519B |
March 31, 2019 | 4.458B |
December 31, 2018 | 4.545B |
September 30, 2018 | 4.329B |
June 30, 2018 | 4.391B |
March 31, 2018 | 4.443B |
December 31, 2017 | 4.429B |
September 30, 2017 | 4.206B |
June 30, 2017 | 4.234B |
Date | Value |
---|---|
March 31, 2017 | 4.076B |
December 31, 2016 | 4.288B |
September 30, 2016 | 4.129B |
June 30, 2016 | 4.169B |
March 31, 2016 | 4.023B |
December 31, 2015 | 4.235B |
September 30, 2015 | 3.990B |
June 30, 2015 | 4.007B |
March 31, 2015 | 3.817B |
December 31, 2014 | 4.125B |
September 30, 2014 | 3.956B |
June 30, 2014 | 3.975B |
March 31, 2014 | 3.734B |
December 31, 2013 | 3.959B |
September 30, 2013 | 3.645B |
June 30, 2013 | 3.745B |
March 31, 2013 | 3.536B |
December 31, 2012 | 3.645B |
September 30, 2012 | 3.332B |
June 30, 2012 | 3.362B |
March 31, 2012 | 3.130B |
December 31, 2011 | 3.281B |
September 30, 2011 | 3.136B |
June 30, 2011 | 3.088B |
March 31, 2011 | 2.879B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.431B
Minimum
Jun 2020
7.936B
Maximum
Jun 2023
5.665B
Average
5.480B
Median
Mar 2021
Revenue (Quarterly) Benchmarks
Eli Lilly and Co | 8.768B |
Genmab A/S | 603.46M |
Ascendis Pharma A/S | 104.16M |
Galecto Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 2.839B |
Total Expenses (Quarterly) | 4.445B |
EPS Diluted (Quarterly) | 1.261 |
Gross Profit Margin (Quarterly) | 85.53% |
Profit Margin (Quarterly) | 35.78% |